Know Cancer

or
forgot password

A Pilot Study to Investigate the Use of Topical Levulan® With Vbeam® Laser for the Treatment of Actinic Keratoses


N/A
18 Years
N/A
Not Enrolling
Both
Precancerous/Nonmalignant Condition

Thank you

Trial Information

A Pilot Study to Investigate the Use of Topical Levulan® With Vbeam® Laser for the Treatment of Actinic Keratoses


OBJECTIVES:

Primary

- To determine, using fluorescence measurements, the protoporphyrin IX (PpIX)
accumulation in thin actinic keratoses (AK) and actinically damaged skin on the face,
scalp, and upper torso (stratum 1) and the PpIX accumulation in thick AK and
actinically damaged skin on the arms and legs (stratum 2) as a function of skin
preparation, aminolevulinic acid (ALA) application time, and body site.

- To determine the extent that the PpIX is photobleached by the treatment light.

Secondary

- To assess the effects of different treatment conditions on acute reactions of AK and
sun damaged skin to ALA-photodynamic therapy (PDT) occurring 24-48 hours after PDT.

- To assess the effects of different treatment conditions on the efficacy of ALA-PDT.

- To examine the histological response to ALA-PDT.

- To determine, using fluorescence measurements, the PpIX accumulation in incidental
thick AK that may occur in stratum 1, and the PpIX accumulation in incidental thin AK
that may occur in stratum 2 as a function of skin preparation, ALA application time and
body site.

- To determine the extent that the PpIX in these incidental lesions is photobleached by
treatment light.

OUTLINE: The randomization is a two-step restricted block process for application time and
skin preparation, followed by randomization for light dose (1 vs 2 pulses) within the
anatomic site. Within each stratum (stratum 1 or 2), lesions in each separate anatomic area
(face and neck, scalp, upper torso; arms, legs) are randomized to receive 1 of 3
pretreatment skin preparation before receiving topical aminolevulinic acid (ALA):
pretreatment with acetone, gentle abrading, or no pretreatment. Patients are randomized to
receive ALA at different times before the photodynamic therapy (PDT).

- Arm I: Patients receive topical ALA 2 hours before PDT.

- Arm II: Patients receive topical ALA 4 hours before PDT.

- Arm III: Patients receive topical ALA 24 hours before PDT. Each anatomic area is
divided into subunits (e.g., right and left arm, right and left side of the face). The
subunits are randomized to receive 1 or 2 pulses of the laser treatment.

- Arm IV: 1 Vbeam laser pulse (photodynamic therapy) is applied to the subunit.

- Arm V: 2 Vbeam laser pulses (photodynamic therapy) are applied to the subunit. Patients
may receive up to 3 treatments (including pretreatment, ALA, and PDT) at least 1 month
apart. Patients with progressive lesions or lesions that have not responded after 3
treatments may receive diagnostic biopsy to check for invasive squamous cell carcinoma
and referred to treatment off study.

Patients undergo biopsies at baseline, before and after ALA application prior to light
treatment, and up to 24 hours after light treatment to analyze cytokines and genes specific
to actinic keratoses.

Inclusion Criteria


DISEASE CHARACTERISTICS:

- Actinic keratosis lesion located in any of the following body sites:

- Stratum 1*: face and neck, scalp, or upper torso

- At least 1 clinically evident thin actinic keratosis on each side of the
midline of any of the above areas

- Stratum 2*: arms or legs

- At least 1 clinically evident thick actinic keratosis on each arm or leg
NOTE: *One patient may be in one or both strata depending on the location
of the lesion(s)

- Lesions to be treated on this protocol must not have been previously treated by other
modalities for at least 2 months prior to study entry

PATIENT CHARACTERISTICS:

- No porphyria or known hypersensitivity to porphyrins

- No known photosensitivity disease

- No known sensitivity to any components of aminolevulinic acid topical solution

- Not pregnant or nursing

PRIOR CONCURRENT THERAPY:

- Other concurrent topical therapies at lesion sites other than those used in this
protocol are allowed

- No other concurrent photosensitizer drugs

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Primary Purpose: Treatment

Outcome Measure:

Protoporphyrin IX (PpIX) accumulation as a function of skin preparation, aminolevulinic acid application time, and body site

Safety Issue:

No

Principal Investigator

Nathalie Zeitouni, MD,

Investigator Role:

Principal Investigator

Investigator Affiliation:

Roswell Park Cancer Institute

Authority:

United States: Federal Government

Study ID:

I 28204

NCT ID:

NCT00524485

Start Date:

May 2005

Completion Date:

Related Keywords:

  • Precancerous/Nonmalignant Condition
  • actinic keratosis
  • Keratosis
  • Keratosis, Actinic
  • Precancerous Conditions

Name

Location

Roswell Park Cancer InstituteBuffalo, New York  14263